SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

NAGLAZYME

BMRN·BIOMARIN PHARMACEUTICAL INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed since 2005.
Why 4/10
NAGLAZYME is an already-approved, marketed drug with no pending PDUFA date, no upcoming pivotal readout, and no scheduled regulatory decision. As a mature commercial product in BioMarin's diversified portfolio, it lacks a hard binary catalyst in the next 12 months, capping the impact score at 4.
Actionable Insight NEUTRAL

NAGLAZYME is a mature, approved product with no pending binary catalysts. The next meaningful event for BioMarin overall is the Q4 2026 earnings report (late February 2027), where NAGLAZYME's steady-state revenue trajectory and any biosimilar entry updates will be visible. For this specific drug, watch for any biosimilar development announcements or label updates, but neither is currently scheduled.

Price Chart

Loading chart...

Executive Summary

NAGLAZYME (galsulfase) is an FDA-approved enzyme replacement therapy for the ultra-rare genetic disorder MPS VI (Maroteaux-Lamy syndrome), developed and marketed by BioMarin Pharmaceutical (NASDAQ: BMRN). Approved in May 2005, it remains the only approved treatment for this indication. The drug generated $485.4 million in 2025 revenue (about 15% of BioMarin's total), though Q3 2026 revenue dipped 11.5% year-over-year to $108 million due to timing of large international orders. With no pending regulatory catalysts, no scheduled pivotal readouts, and no biosimilar competition yet on the market despite expired exclusivity, NAGLAZYME is a stable but mature commercial asset within BioMarin's now-larger and more diversified portfolio following the $4.8 billion Amicus Therapeutics acquisition.

How It Works

NAGLAZYME is an enzyme replacement therapy for patients with MPS VI (Maroteaux-Lamy syndrome), a rare genetic disorder where the body lacks an enzyme needed to break down certain complex sugars (GAGs). The drug is a manufactured version of the missing human enzyme, given as a weekly intravenous infusion, that helps break down these accumulated sugars to improve walking and stair-climbing capacity.

Trial Status

NAGLAZYME was approved by the FDA on May 31, 2005, based on a 24-week Phase 3 study in 39 MPS VI patients that showed improvements in walking and stair-climbing capacity. It is a fully commercialized product with no active pivotal trials for new indications.

The Two-Sided Case

▲ Bull Case4
NAGLAZYME remains the first and only FDA-approved enzyme replacement therapy for MPS VI (Maroteaux-Lamy syndrome), a rare, life-threatening genetic disorder with no other approved treatment options (source: FDA label and BioMarin press release).
The drug generated $485.4 million in 2025 revenue, a meaningful and steady contributor to BioMarin's enzyme therapies franchise, which grew 6% year-over-year in Q1 2026 (source: BioMarin Q1 2026 press release, TradingView 10-K analysis).
No biosimilar competitor has entered the market despite expired exclusivity, suggesting high barriers to entry for a complex biologic enzyme replacement therapy serving a very small patient population (source: Synapse/Patsnap analysis).
BioMarin's analyst consensus is bullish: 27 analysts rate it Buy/Strong Buy (27 of 35 total ratings), with a mean price target of $91.56, implying roughly 57% upside from the current ~$58 price.
▼ Bear Case4
NAGLAZYME revenue declined 11.5% year-over-year in Q3 2026 to $108 million, driven by timing of large international orders, showing lumpiness in a small-market product.
Patent and regulatory exclusivity have expired (projected loss of exclusivity around 2017 per CliffBio), leaving the drug exposed to eventual biosimilar competition, though none has entered to date (source: DrugPatentWatch).
NAGLAZYME is a small part of BioMarin's now-diversified portfolio (post-Amicus acquisition), limiting its individual impact on the stock. BioMarin's 2025 total revenue was $3.2 billion, with NAGLAZYME contributing $485.4 million or about 15% (source: TradingView 10-K analysis).
Elevated short-sale volume relative to BMRN's own history (z-score 1.63, recent ratio 59.8% vs baseline 54.0%) and multiple institutional exits/trims in Q2 2026 (Citadel near-exit, Point72 exit, Wellington exit) signal bearish sentiment around the stock overall.

Upcoming Catalysts

  • No upcoming binary catalysts for NAGLAZYME specifically. The drug is a mature commercial product with no pending regulatory decisions or pivotal readouts.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report

Sources · 11

Hover a chip for the title
1 accessdata.fda.gov2 biomarin.com3 tradingview.com4 prnewswire.com5 biomarin.com6 drugpatentwatch.com7 cliffbio.com8 synapse.patsnap.com9 marketchameleon.com10 benzinga.com11 news.alphastreet.com